Skip to content

Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use

Sebastian J. Padayatty, He Sun, Yaohui Wang, Hugh D. Riordan, Stephen M. Hewitt, Arie Katz, ROBERT A. WESLEY, Mark Levine

Annals of Internal Medicine · 2004 · 1,015 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., WESLEY, R. A., & Levine, M. (2004). Vitamin C pharmacokinetics: Implications for oral and intravenous use. Annals of Internal Medicine, 140(7), 533–537. https://doi.org/10.7326/0003-4819-140-7-200404060-00010

In text: (Padayatty et al., 2004)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Vitamin C at high concentrations is toxic to cancer cells in vitro. Early clinical studies of vitamin C in patients with terminal cancer suggested clinical benefit, but 2 double-blind, placebo-controlled trials showed none. However, these studies used different routes of administration. OBJECTIVE: To determine whether plasma vitamin C concentrations vary substantially with the route of administration. DESIGN: Dose concentration studies and pharmacokinetic modeling. SETTING: Academic medical center. PARTICIPANTS: 17 healthy hospitalized volunteers. MEASUREMENTS: Vitamin C plasma and urine concentrations were measured after administration of oral and intravenous doses at a dose range of 0.015 to 1.25 g, and plasma concentrations were calculated for a dose range of 1 to 100 g. RESULTS: Peak plasma vitamin C concentrations were higher after administration of intravenous doses than after administration of oral doses (P < 0.001), and the difference increased according to dose. Vitamin C at a dose of 1.25 g administered orally produced mean (+/-sd) peak plasma concentrations of 134.8 +/- 20.6 micromol/L compared with 885 +/- 201.2 micromol/L for intravenous administration. For the maximum tolerated oral dose of 3 g every 4 hours, pharmacokinetic modeling predicted peak plasma vitamin C concentrations of 220 micromol/L and 13 400 micromol/L for a 50-g intravenous dose. Peak predicted urine concentrations of vitamin C from intravenous administration were 140-fold higher than those from maximum oral doses. LIMITATIONS: Patient data are not available to confirm pharmacokinetic modeling at high doses and in patients with cancer. CONCLUSIONS: Oral vitamin C produces plasma concentrations that are tightly controlled. Only intravenous administration of vitamin C produces high plasma and urine concentrations that might have antitumor activity. Because efficacy of vitamin C treatment cannot be judged from clinical trials that use only oral dosing, the role of vitamin C in cancer treatment should be reevaluated.

  1. Chlorophyll fluorescence—a practical guide2000
  2. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal2014
  3. The Chemistry behind Antioxidant Capacity Assays2005
  4. Oxidants, antioxidants, and the degenerative diseases of aging.1993
  5. Standardized Methods for the Determination of Antioxidant Capacity and Phenolics in Foods and Dietary Supplements2005

Metadata from OpenAlex (CC0). Citations are generated from the published record.